Healthcare
Heidelberg Pharma has announced that the first patient has been dosed in its Phase I trial assessing Amanitin-based antibody-drug conjugate (ADC) candidate HDP-102 for non-Hodgkin lymphoma (NHL). HDP-102 is the company’s second candidate derived from its proprietary Amanitin-based ADC technology platform to enter the clinic.
The Phase I trial is a multicentre, multinational, open-label study, designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HDP-102 in patients with relapsed or refractory B-cell malignancies, with the additional objective of determining the recommended dose for subsequent clinical development efforts.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment